ENANTA PHARMACEUTICALS INC (ENTA) Stock Income Statement
NASDAQ:ENTA • US29251M1062
13.89 USD
+0.03 (+0.22%)
At close: Feb 18, 2026
13.89 USD
0 (0%)
After Hours: 2/18/2026, 8:00:01 PM
| TTM (2025-12-31) | 2025 (2025-9-30) | 2024 (2024-9-30) | 2023 (2023-9-30) | 2022 (2022-9-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 66.98M | 65.32M | 67.64M | 79.20M | 86.20M | |||
| Operating Expenses | 140.04M | 150.67M | 189.33M | 216.40M | 210.00M | |||
| Research and Development | 99.94M | 106.74M | 131.48M | 163.50M | 164.50M | |||
| Selling, General, and Administrative Expenses | 40.10M | 43.93M | 57.85M | 52.90M | 45.50M | |||
| Operating Income | -73.06M | -85.35M | -121.69M | -137.20M | -123.80M | |||
| Interest Income/Expense | 302.00K | 1.80M | 3.90M | 6.20M | 1.70M | |||
| Income Before Taxes | -72.76M | -83.55M | -117.79M | -131.00M | -122.20M | |||
| Income Tax | -1.22M | -1.66M | -1.74M | 2.80M | -400.00K | |||
| Net Income | -71.54M | -81.89M | -116.05M | -133.80M | -121.80M | |||
| EBITDA | N/A | -80.76M | -119.36M | -134.83M | -120.83M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.20 | -3.84 | -5.49 | -6.38 | -5.91 | |||
| Non GAAP EPS | -3.20 | -3.83 | -5.48 | -6.37 | -5.91 | |||
| Statistics | ||||||||
| Profit Margin | -106.80% | -125.36% | -171.58% | -168.94% | -141.30% | |||
| Operating Profit Margin | -109.08% | -130.65% | -179.92% | -173.23% | -143.62% | |||
All data in USD